Key points:
1. Poland plans to pass a law in the third quarter of 2025 to completely ban the use of disposable e-cigarettes (whether or not they contain nicotine).
2. The draft emphasizes that testing of e-cigarette liquid ingredients will be authorized, and only products that produce a tobacco flavor will be allowed for sale.
3. The government will restrict the sale of new nicotine products, banning nicotine-containing chewing gum, tablets, and other products, and requiring strict testing and registration.
2Firsts, reporting from Shenzhen - The Polish Ministry of Health is set to draft a legislation that will prohibit the use of disposable e-cigarettes in Poland, regardless of whether they contain nicotine.
The government is planning to pass this law in the third quarter of 2025, as outlined in the Ministerial Council's legislative agenda.
The proposed regulation will further restrict the use of disposable e-cigarettes, not only for those under 18 years old, but even for adult e-cigarette users.
The legislative agenda states that:
"The proposed regulations have the most impact on so-called young people. E-cigarettes, whether they contain nicotine or other substances, are products that pose a clear threat to public health. These products contain highly addictive substances and other accompanying substances, which, when absorbed by the body, have unknown health effects on those who use these products."
The draft legislation will also authorize the director of the Chemical Management Bureau to order testing of e-cigarette liquid ingredients, and to list the names of laboratories responsible for carrying out such tests.
At the same time, in the future only products containing ingredients that produce tobacco scent are allowed to be sold. The government also hopes to limit the market presence of new nicotine products, including so-called "nicotine pouches," through legislation.
In addition, the sale of chewing gum, lozenges, nasal sprays, and beverages containing nicotine is explicitly prohibited. These products must undergo rigorous testing and registration by the pharmaceutical management to confirm their effectiveness and safety.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
